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tant role in the regulation of cell proliferation and survival, in response
to various environmental cues, e.g., oxidative stress and inﬂammatory
cytokines (Cuenda and Rousseau, 2007). p38 MAPK activity is elevated
in types of cancer, including colorectal cancer (CRC) (Gupta et al.,
2014), and accordingly, several p38 inhibitors (p38is) have been in
early clinical trials. However, surprisingly, none of the p38is has
shown positive effects on CRC. This remains mysterious.
In this issue of EBioMedicine, Zhang et al. (2015), for the ﬁrst time,
reported opposite responses of two subgroups of CRC cells to p38is. In
the ﬁrst subgroup (including RKO, CACO2 and SW480), named p38i-
inhibited group, p38 inhibitor (p38i) SB202190 inhibited cell prolifera-
tion and induced apoptosis; while in the second subgroup (including
HCT116, SW1116 and SW620), designated p38i-stimulated group,
SB202190 increased cell proliferation and survival. Similar results
were observed in LY2228820 and BIRB796, two other p38is. The ﬁnd-
ings were veriﬁed in CRC xenografts in mice, indicating that there
exist two subgroups of CRC cells, which respond to p38is differentially.
Interestingly, Zhang et al. (2015) also foundopposing effects of p38is
on mTORC1 in the two subgroups of CRC cells, correlating with the ef-
fects on cell growth. Since SB202190 inhibits mTORC1 through MAPK-
activated protein kinase 2 (MK2)-dependent phosphorylation of TSC2
(S1254) (Li et al., 2003), and MK2 is directly regulated by p38 MAPK
(Cuenda and Rousseau, 2007). Zhang et al. (2015) hypothesized that
the opposite effects of p38is on mTORC1 in the CRC cells link to the sta-
tus of TSC1/2 complex, a negative regulator of mTORC1 (Inoki et al.,
2002). The results support their hypothesis, as silencing TSC1 or TSC2
abrogated the negative or positive effects of SB202190 on mTORC1
and cell growth.
TSC2 can be phosphorylated byAkt at T1462, p38/MK2 at S1254, and
ERK–RSK at S664/S1798 (Inoki et al., 2002; Li et al., 2003; Roux et al.,
2004; Ma et al., 2005). Zhang et al. (2015) also found that TSC2 phos-
phorylation differed between the two subgroups of CRC cells, in re-
sponse to p38i. In the p38i-inhibited group, SB202190 suppressed
p38/MK2-mediated TSC2 phosphorylation (S1254), causing activation
of TSC1/2 and thereby inhibition of mTORC1, but had no effects on
Akt/ERK–RSK-mediated TSC2 phosphorylations. In contrast, in theDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.11.031.
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and activation of mTORC1. Similarly, Akt or p38/MK2-mediated TSC2
phosphorylations were not inﬂuenced by SB202190. Hence, the results
suggest that p38/MK2 and ERK/RSK mediate the opposing effects of
p38i on mTORC1 via regulating different phosphorylation sites of TSC2
in the two subgroups.
Protein phosphatase 2A (PP2A), a serine–threonine phosphatase,
consists of the structural A subunit, regulatory B subunit, and catalytic
C subunit (Seshacharyulu et al., 2013). It has been described that p38
MAPK negatively regulates ERK in a PP2A-dependent manner in rat
cardiac ventricular myocytes (Liu and Hofmann, 2004). Likely, the
differential effects of p38i on TSC phosphorylation are related to
PP2AC levels in the two subgroups of CRC cells. To this end, Zhang
et al. (2015) examined PP2AC expression in the cells. They found that
PP2AC was expressing at a much lower level in p38i-inhibited group
than in p38i-stimulated group, limiting the negative regulation of p38
on ERK. Silencing PPA2C in the p38i-stimulated CRC cells diminished
the activation effect of SB202190 on mTORC1, and reprogrammed the
selective response of TSC2 phosphorylation to the p38i from p38–
ERK–RSK–TSC2 to p38–MK2–TSC2. On the contrary, overexpressing
PP2AC in the p38i-inhibited CRC cells reduced the inhibitory effect of
SB202190 on mTORC1, and reprogrammed the selective response of
TSC2 phosphorylation to the p38i from p38–MK2–TSC2 to p38–ERK–
RSK–TSC2. Thus, the data support the notion that PP2AC level in CRC
cells determines their differential responses to p38i.
To demonstratewhether the level of PP2AC expression in CRC can be
used as a biomarker for treatment, patient-derived xenograft (PDX)
mouse models were employed (Zhang et al., 2015). They found that
human CRC tumors expressing low levels of PP2AC showed good re-
sponse to SB202190,whereas humanCRC tumors expressinghigh levels
of PP2AC displayed poor or adverse response to SB202190. Thus, the re-
sults suggest that PP2AC expression level may serve as a useful bio-
marker for p38 targeted therapy.
Since p38i activation of mTORC1 correlates with the resistance in
p38i-stimulated subgroup, Zhang et al. (2015) also tested whether
mTOR kinase inhibitors were able to overcome the resistance of CRC
cells to p38i. They found that SB202190 alone stimulated SW620 xeno-
graft growth, and mTOR kinase inhibitor OSI-027 alone did not inhibit
SW620 tumor growth. When combined, the two drugs remarkably
inhibited the tumor growth and induced apoptosis of SW620 cells.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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combinational chemotherapy.
In summary, the ﬁndings from Zhang et al. (2015) shed new light on
targeted chemotherapy and combinational chemotherapy. The intrinsic
properties of different tumor cells may render differential responses to
the same treatment. Hence, identifying the heterogeneity within one
tumor type is crucial for personalized treatment. Undoubtedly, more ef-
forts are needed to validate whether PP2AC expression level can serve
as a biomarker for p38 targeted therapy. Also, it would be interesting
to studywhether PP2AC level is also amajor determinant for other can-
cers (e.g., lung, breast or prostate cancer) to respond to p38 targeted
therapy. The ﬁnding of opposing effects of p38is on two subgroups of
CRC cells gives us warning in proper categorization of patients to
avoid promoting tumor growth through chemotherapies.
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